MCL1 and B-cell chronic lymphocytic leukemia: For drug resistance in CLL due to MCL-1 upregulation induced by chromatin alterations such as trisomy 12 mutations, the combination of MCL-1 inhibitors with BCL-2 inhibitors produced some results, but further studies are needed to evaluate whether patients’ benefits outweighed the toxicity with these combinations (43).